Clinical Trials Browser

INDUSTRY × Multiple Myeloma × selinexor × Clear all

NCT06158841 2026-03-13

CERVINO

Phase 3 Recruiting

Multiple Myeloma

NCT07215832 2026-03-02

KEAP

GynecologicLymphoidMyeloidPlasma cellSarcoma

Multiple Myeloma, Sarcoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Endometrial Neoplasms, Primary Myelofibrosis

NCT07138209 2026-02-27

A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

Phase 3 Recruiting

Multiple Myeloma, Recurrence

NCT04414475 2026-02-02

A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.

Phase 2 Recruiting

Multiple Myeloma

NCT05954780 2026-01-14

SEATTLE

Active not recruiting

Multiple Myeloma

NCT02343042 2025-12-22

STOMP

Phase 1/2 Recruiting

Multiple Myeloma, Recurrence

NCT04782687 2025-01-16

Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma

Phase 2 Active not recruiting

Multiple Myeloma, Neoplasms, Neoplasms, Plasma Cell

NCT03110562 2024-08-21

BOSTON

Phase 3 Completed

402 enrolled 22 charts 2 FDA

Multiple Myeloma, Recurrence

NCT04519476 2023-10-31

Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.

Phase 1 Unknown

Multiple Myeloma

NCT03944057 2023-06-15

MARCH

Phase 2 Completed

82 enrolled 9 charts

Multiple Myeloma, Recurrence

NCT01607892 2023-01-26

Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer

Phase 1 Completed

286 enrolled 26 charts

DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02336815 2023-01-26

STORM

Phase 2 Completed

202 enrolled 30 charts 1 FDA

Multiple Myeloma

NCT02389543 2023-01-26

SLAM

Phase 1/2 Withdrawn

Multiple Myeloma, Recurrence

NCT02628704 2023-01-26

SCORE

Phase 2 Withdrawn

Multiple Myeloma